SUSVIMO™ is an ocular implant for intravitreal use, with continuous delivery of the vascular endothelial growth factor VEGF inhibitor ranibizumab.

**INDICATION**

Treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor.

**HCPCS CODE**

J2779 Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

**INITIAL FILL AND IMPLANTATION (In an ASC or Hospital Outpatient Department)**

CPT® code 67027 Implantation of intravitreal drug delivery system (eg, ganciclovir implant), includes concomitant removal of vitreous

**2024 National Payer Allowables and Global Period**

<table>
<thead>
<tr>
<th>Physician Allowable</th>
<th>Hospital Allowable*</th>
<th>ASC Allowable*</th>
<th>Global Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facility: $836.52</td>
<td>Office: N/A</td>
<td>Medicare: $15,038.42</td>
<td>Medicare: $2,019.42</td>
</tr>
</tbody>
</table>

*Pass-through status for drug, facility bills separately

**National Correct Coding Initiative Edits**

67027 is bundled with these CPT codes when performed on the same eye, same day, and same surgical session:

12011, 12013, 12014, 12015, 12016, 12017, 12018, 12020, 12021, 12051, 12052, 12053, 12054, 12056, 12057, 13151, 13152, 13153, 67005, 67010, 67015, 67025, 67028, 67036, 67121, 67500, 67516, 92012, 92014, 92018, 92019, 92201, 92202, 96365, 96366, 99211, 99212, 99213, 99214, 99215, 99221, 99222, 99223, 99231, 99232, 99233, 99234, 99235, 99236, 99238, 99239, 99242, 99244, 99245, 99252, 99253, 99254, 99255, 99291, 99292, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99315, 99316, 99347, 99348, 99349, 99350, 99374, 99375, 99377, 99378, GO463. **Mutually Exclusive:** 99150, 99155, 99156, 99157, 99446, 99447, 99448, 99449, 99495, 99496

**Billing Guidelines**

<table>
<thead>
<tr>
<th>What Physicians Bill</th>
<th>What Facilities Bill</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT code 67027, append modifier -RT or -LT Procedure note should state: 2 mg/0.02 mL used and 8 mg/0.08 mL wasted.</td>
<td>CPT code 67027 and HCPCS code J2779 with 20 units On a separate line, report J2779-JW with 80 units (-JW modifier reports wastage of 1 unit or greater)</td>
</tr>
</tbody>
</table>

**National Drug Code (NDC)**

The NDC should be reported on the CMS-1500 claim form in item 24a or EDI loop 2410 as an 11-digit NDC code in 5-4-2 format, preceded by “N4” qualifier.

- 10-digit: 50242-078-55 converts to 11-digit (5-4-2 format for billing): 50242-0078-55

REFILL-EXCHANGE PROCEDURE

CPT code 67028 Intravitreal injection of a pharmacologic agent (separate procedure)

2024 National Payer Allowables and Global Period

<table>
<thead>
<tr>
<th>Physician Allowable</th>
<th>Hospital Allowable</th>
<th>ASC Allowable</th>
<th>Global Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facility: $90.21 / RVU: 2.71</td>
<td>Medicare: $322.68 When performed in the HOPD or ASC, the facility is paid for the drug.</td>
<td>Medicare: $60.58 When performed in the HOPD or ASC, the facility is paid for the drug.</td>
<td>0 days</td>
</tr>
<tr>
<td>Office : $112.18 / RVU: 3.37 When performed in the office setting, the physician bills the drug</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

National Correct Coding Initiative Edits

67028 is bundled with these CPT codes when performed on the same eye, same day, and same surgical session:

12011, 12013, 12014, 12015, 12016, 12017, 12018, 12020, 12021, 12051, 12052, 12053, 12054, 12055, 12056, 12057, 13151, 13152, 13153, 67500, 68200, 92018, 92019, 92201, 92202, 92203, 96365, 96366, 99211, 99212, 99213, 99214, 99215, 99221, 99222, 99223, 99231, 99232, 99233, 99234, 99235, 99236, 99238, 99239, 99242, 99243, 99244, 99245, 99252, 99253, 99254, 99255, 99291, 99292, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99315, 99316, 99347, 99348, 99349, 99350, 99374, 99375, 99377, 99378, 99495, 99496, G0463.

Mutually Exclusive: 99150, 99155, 99156, 99157, 99446, 99447, 99448

Billing Guidelines When Refill-Exchange Is Performed in the Office-Setting

<table>
<thead>
<tr>
<th>What Physicians Bill</th>
<th>Payment</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT code 67028, append anatomical modifier, -RT or -LT, and HCPCS code J2779, append modifier -JZ and report 100 units (-JZ modifier reports no wastage) Procedure note should state: “Withdrew the entire contents of the Susvimo vial into a syringe to the 0.1 mL dose mark. The entire contents of the syringe (0.1 mL) were used to flush the medication and provide the appropriate 2 mg continuous dosage into the implant. No wastage remained after the refill procedure was completed.” Comprehensive documentation requirements for intravitreal injections can be accessed at <a href="https://www.aao.org/retinapm">https://www.aao.org/retinapm</a>.</td>
<td>In Q3 2024, the CMS Average Sales Price (ASP) payment limit for HCPCS code J2779 is $80.489 per unit. Current payment limits can be accessed at <a href="https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files">https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files</a>.</td>
</tr>
</tbody>
</table>

National Drug Code (NDC)

The NDC should be reported on the CMS-1500 claim form in item 24a or EDI loop 2410 as an 11-digit NDC code in 5-4-2 format, preceded by “N4” qualifier.

- 10-digit: 50242-078-12 converts to 11-digit (5-4-2 format for billing): 50242-0078-12
MODIFIERS

-RT Right eye
-LT Left eye
-JW Drug amount discarded/not administered to any patient
-JZ Zero drug amount discarded/not administered to any patient

ICD-10-CM CODES*

H35.3211 Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212 Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3221 Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222 Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3231 Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232 Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization

*To code to the highest level of specificity and avoid claim denials do not report unspecified stage and/or eye H35.3210, H35.3220, H35.3230, H35.3290, H35.3291, H35.3292

IMPLANT REMOVAL

For the removal of implant, report CPT code 67121, Removal of implanted material, posterior segment, intraocular

Supported by Genentech

A Member of the Roche Group

DISCLAIMER: The Academy does not recommend or endorse any specific tests, drugs, devices, products and services of others that may be mentioned or referenced in this publication. Any financial support has no influence on the editorial content or presentation and any acknowledgment of such support is not an implied or express endorsement of any product, service or company.

All information provided by the American Academy of Ophthalmology, its employees, agents or representatives participating in the Academy’s coding service is as current and reliable as reasonably possible. The Academy does not guarantee or warrant that either public or private payers will agree with the Academy’s information or recommendations. The Academy shall not be liable to you or any other party to any extent whatsoever for errors in, or omissions from, any such information provided by the Academy, its employees, agents or representatives. The Academy’s sole liability for any claim connected to its provision of coding information or services shall be limited to the amount paid by you to the Academy for the information or coding service.

CPT is the registered trademark of the American Medical Association.